Capital Research Global Investors Lowers Stock Position in IDEXX Laboratories, Inc. $IDXX

Capital Research Global Investors cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 607,754 shares of the company’s stock after selling 82,847 shares during the period. Capital Research Global Investors’ holdings in IDEXX Laboratories were worth $411,164,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Empowered Funds LLC boosted its position in IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after purchasing an additional 95 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in IDEXX Laboratories during the second quarter worth approximately $265,000. Jump Financial LLC boosted its position in IDEXX Laboratories by 1,006.4% during the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after purchasing an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC purchased a new position in IDEXX Laboratories during the second quarter worth approximately $164,000. Finally, Sei Investments Co. boosted its position in IDEXX Laboratories by 218.7% during the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after purchasing an additional 82,755 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

IDXX opened at $562.16 on Monday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company has a market cap of $44.34 billion, a price-to-earnings ratio of 41.40, a PEG ratio of 3.08 and a beta of 1.56. IDEXX Laboratories, Inc. has a 52-week low of $506.91 and a 52-week high of $769.98. The firm’s fifty day simple moving average is $563.05 and its two-hundred day simple moving average is $631.88.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue was up 14.3% compared to the same quarter last year. During the same period last year, the firm posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. UBS Group lowered their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Piper Sandler decreased their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Citigroup started coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Finally, Stifel Nicolaus decreased their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.